Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

CREXONT

CARBIDOPA; LEVODOPA

Standard Dose
70MG;280MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CREXONT is listed in Drugs@FDA under application 217186 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CARBIDOPA; LEVODOPA Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 70MG;280MG Sponsor IMPAX Submission history Latest submission status date: 2026-03-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview CREXONT is listed in Drugs@FDA under application 217186 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CARBIDOPA; LEVODOPA Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 70MG;280MG Sponsor IMPAX Submission history Latest submission status date: 2026-03-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
CREXONT (CARBIDOPA; LEVODOPA) | Drug Monograph | MedicHelpline